Pharmaceutical producer Hemofarm has expanded its renewable energy footprint with the activation of a large-scale rooftop solar installation at its manufacturing complex in Vršac. The Serbian company, part of Germany’s Stada Group, invested 3 million euros in the project, marking one of the most substantial industrial solar undertakings in the country to date.
The newly completed system delivers 4 MW of installed capacity and covers roughly 21,000 square meters of roof space. Around 8,000 photovoltaic modules have been mounted across the facility, enabling the plant to generate close to 5 million kWh of clean electricity annually. According to company data, this output will lower the site’s reliance on grid-supplied power by approximately 12% over the course of a year.
Seasonal performance is expected to be particularly significant. During peak summer demand, when electricity usage typically surges, the solar array could meet as much as half of the factory’s total energy requirements. In addition to reducing external power consumption, the installation is projected to cut carbon dioxide emissions by between 3,000 and 3,500 tons each year.
Hemofarm’s management described the initiative as a cornerstone of its long-term sustainability strategy. The company aims to decrease its environmental impact while enhancing supply security and reinforcing the resilience of its operations. Expanding the share of renewables in its energy mix is seen as essential for maintaining competitiveness and ensuring stable growth in the years ahead.
The project was delivered under a full turnkey arrangement. Besides installing solar panels, the works included strengthening the building’s roof structure to support the system and deploying a sophisticated digital monitoring platform. This technology will track performance in real time, helping to maximize efficiency and maintain dependable operation across the facility.
